Kevin Feeley Sells 5,706 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 5,706 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $76.80, for a total value of $438,220.80. Following the completion of the sale, the chief financial officer directly owned 27,148 shares in the company, valued at approximately $2,084,966.40. The trade was a 17.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, March 4th, Kevin Feeley sold 6,187 shares of GeneDx stock. The stock was sold at an average price of $78.61, for a total value of $486,360.07.
• On Thursday, January 29th, Kevin Feeley sold 317 shares of GeneDx stock. The shares were sold at an average price of $93.99, for a total value of $29,794.83.

GeneDx Price Performance

Shares of NASDAQ WGS opened at $70.69 on Thursday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.34 and a current ratio of 2.46. The firm has a fifty day moving average of $92.64 and a 200 day moving average of $119.65. The firm has a market cap of $2.07 billion, a PE ratio of -94.25 and a beta of 2.03. GeneDx Holdings Corp. has a one year low of $55.17 and a one year high of $170.87.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.03. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. The business had revenue of $120.99 million for the quarter, compared to the consensus estimate of $120.80 million. As a group, research analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on WGS shares. Piper Sandler reiterated an “overweight” rating and issued a $130.00 price objective (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Wells Fargo & Company raised GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 target price for the company in a report on Monday, February 9th. Wall Street Zen downgraded GeneDx from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. Finally, Zacks Research upgraded GeneDx from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $150.71.

Institutional Trading of GeneDx

Several large investors have recently bought and sold shares of the business. Arizona State Retirement System raised its holdings in GeneDx by 2.1% in the 4th quarter. Arizona State Retirement System now owns 5,594 shares of the company’s stock valued at $728,000 after acquiring an additional 113 shares during the last quarter. Cerity Partners LLC lifted its stake in GeneDx by 6.0% in the 4th quarter. Cerity Partners LLC now owns 2,527 shares of the company’s stock worth $329,000 after purchasing an additional 142 shares in the last quarter. Main Management ETF Advisors LLC boosted its holdings in shares of GeneDx by 1.0% during the 4th quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock worth $2,037,000 after purchasing an additional 160 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of GeneDx by 5.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock worth $399,000 after purchasing an additional 181 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its position in shares of GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.